Organon Continues Building Women’s Health Portfolio With Forendo Buyout
The Finnish company’s endometriosis candidate could offer a better safety profile and be the first drug to address disease progression, Organon claims. Q3 revenues declined slightly due to pandemic, generic competition.
You may also be interested in...
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
The new capital will allow the VC arm to create and finance "a new and larger portfolio of innovative companies that align with the future strategies" of Merck's businesses.
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.